Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms ...

The US federal government has awarded $99 million in funding for a one-shot vaccine against the Bundibugyo virus (BDBV), the ...

Dren Bio has closed a sizeable private financing round, raising $350 million to fund pivotal trials of its potentially ...

Among the highlights of UK Chancellor John Healey's first Budget was more than £1 billion in investment by Convatec, Vertex ...

While Lilly's injectable incretin products are romping away, the performance of its oral GLP-1 agonist Foundayo (orforglipron) – currently competing head-to-head with Novo's first-to-market Wegovy ...

Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new company, focused on central nervous system (CNS) diseases, with combined revenues of around $2.2 ...

Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively ...

While Anthropic has not disclosed the number of shares to be released, their price range, or a date for the listing, ...

Switzerland's Ferring Pharma has reached an agreement to buy US women's health startup Gameto for up to $1.38 billion, ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set to ...

The Novartis Pavillon in Park South of the Novartis Campus in Basel, Switzerland. Novartis's third-quarter results included a ...